Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TNP 351

Known as: TNP-351 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Methotrexate
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Novel pyrrolo[2,3-d]pyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis
N-{4-[3-(2,4-Diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl}-l-glutamic acid (TNP-351), characterized by a pyrrolo[2,3-d… Expand
  • figure 1
Highly Cited
2003
Highly Cited
2003
A new and efficient synthesis of pyrrolo[2,3-d]pyrimidine anticancer agents: Alimta (LY231514, MTA), homo-Alimta, TNP-351, and some aryl 5-substituted pyrrolo[2,3-d]pyrimidines.
Alimta, as well as homo-Alimta, a nonbridged analogue of Alimta, and TNP-351 have been prepared by a new method that involves… Expand
2000
2000
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. III. Synthesis and biological properties of N(omega)-masked ornithine analogs.
The glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5-yl)propyl]benzoyl]-L-g lutamic acid (1b, TNP-351… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
1997
1997
Growth inhibitory effects of antifolates against an adriamycin-resistant human small cell lung cancer cell line.
We have established an Adriamycin (ADM)-resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM 100, which shows… Expand
1996
1996
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. II. Synthesis and antitumor activity of N5-substituted glutamine analogs.
The glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2, 3-d]pyrimidin-5-yl)propyl]benzoyl]-L-glutamic acid (1b, TNP-351… Expand
1996
1996
A Ring-Transformation/Ring-Annulation Strategy for the Synthesis of the DHFR Inhibitor, TNP-351: A Correction.
 
1995
1995
Non-glutamate type pyrrolo[2,3-d]pyrimidine antifolates. I: Synthesis and biological properties of pyrrolo[2,3-d]pyrimidine antifolates containing tetrazole congener of glutamic acid.
Either the alpha- or gamma-carboxyl group of the glutamic acid moiety of N-[4-[3-(2,4-diamino-7H-pyrrolo[2,3-d]pyrimidin-5- yl… Expand
1995
1995
[The clinical phase I study of TNP-351. The TNP-351 Research Committee].
The clinical phase I study of TNP-351, an antifolate drug having a novel structure, was performed through a multicenter… Expand
1994
1994
Pharmacodynamics and factorial analysis of an anticancer agent, TNP-351.
 
1994
1994
Pharmacodynamics and factorial analysis of an anticancer agent, TNP-351.
 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE